{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:28:42Z","timestamp":1787682522890,"version":"build-2784847793"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tapentadol (TAP) and oxycodone\/naloxone (OXN) potentially offer an improved opioid tolerability. However, real-world studies in chronic non-cancer pain (CNCP) remain scarce. Our aim was to compare effectiveness and security in daily pain practice, together with the influence of pharmacogenetic markers. An observational study was developed with ambulatory test cases under TAP (n\u2009=\u2009194) or OXN (n\u2009=\u2009175) prescription with controls (prescribed with other opioids (control), n\u2009=\u2009216) CNCP patients. Pain intensity and relief, quality of life, morphine equivalent daily doses (MEDD), concomitant analgesic drugs, adverse events (AEs), hospital frequentation and genetic variants of <jats:italic>OPRM1<\/jats:italic> (rs1799971, A118G) and <jats:italic>COMT<\/jats:italic> (rs4680, G472A) genes, were analysed. Test CNCP cases evidenced a significantly higher pain relief predictable due to pain intensity and quality of life (R<jats:sup>2<\/jats:sup>\u2009=\u20090.3), in front of controls. Here, OXN achieved the greatest pain relief under a 28% higher MEDD, 8\u201313% higher use of pregabalin and duloxetine, and 23% more prescription change due to pain, compared to TAP. Whilst, TAP yielded a better tolerability due the lower number of 4 [0\u20136] AEs\/patient, in front of OXN. Furthermore, OXN <jats:italic>COMT<\/jats:italic>-AA homozygotes evidenced higher rates of erythema and vomiting, especially in females. CNCP real-world patients achieved higher pain relief than other traditional opioids with a better tolerability for TAP. Further research is necessary to clarify the potential influence of <jats:italic>COMT<\/jats:italic> and sex on OXN side-effects.\n<\/jats:p>","DOI":"10.1038\/s41598-022-13085-5","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T18:03:02Z","timestamp":1655402582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Oxycodone\/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study"],"prefix":"10.1038","volume":"12","author":[{"given":"Jordi","family":"Barrachina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Margarit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Muriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"L\u00f3pez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"L\u00f3pez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"Vara-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Planelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-del-Mar","family":"Inda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Peir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"13085_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","volume":"65","author":"D Dowell","year":"2016","unstructured":"Dowell, D., Haegerich, T. M. & Chou, R. CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016. MMWR Recommend. Rep. 65, 1\u201349 (2016).","journal-title":"MMWR Recommend. Rep."},{"key":"13085_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/j.1526-4637.2008.00425.x","volume":"9","author":"J Hardt","year":"2008","unstructured":"Hardt, J., Jacobsen, C., Goldberg, J., Nickel, R. & Buchwald, D. Prevalence of chronic pain in a representative sample in the United States. Pain Med. 9, 803\u2013812 (2008).","journal-title":"Pain Med."},{"key":"13085_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13155","author":"J Muriel","year":"2019","unstructured":"Muriel, J. et al. Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients. Basic Clin. Pharmacol. Toxicol. https:\/\/doi.org\/10.1111\/bcpt.13155 (2019).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"13085_CR4","doi-asserted-by":"publisher","first-page":"e0167479","DOI":"10.1371\/journal.pone.0167479","volume":"11","author":"K Fernandes","year":"2016","unstructured":"Fernandes, K. et al. High-Dose opioid prescribing and opioid-related hospitalization: A population-based study. PLoS ONE 11, e0167479 (2016).","journal-title":"PLoS ONE"},{"key":"13085_CR5","volume-title":"The Prescription Opioid Epidemic: An Evidence-Based Approach","author":"G Alexander","year":"2015","unstructured":"Alexander, G., Frattaroli, S. & Gielen, A. The Prescription Opioid Epidemic: An Evidence-Based Approach (Johns Hopkins Bloomberg School of Public Health, 2015)."},{"key":"13085_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2049463712438493","volume":"6","author":"H Pathan","year":"2012","unstructured":"Pathan, H. & Williams, J. Basic opioid pharmacology: An update. Br. J. Pain 6, 11\u201316 (2012).","journal-title":"Br. J. Pain"},{"key":"13085_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2147\/JPR.S112418","volume":"9","author":"MA Ueberall","year":"2016","unstructured":"Ueberall, M. A. & Mueller-Schwefe, G. H. H. Efficacy and tolerability balance of oxycodone\/naloxone and tapentadol in chronic low back pain with a neuropathic component: A blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations. J. Pain Res. 9, 1001\u20131020 (2016).","journal-title":"J. Pain Res."},{"key":"13085_CR8","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.jpainsymman.2013.02.009","volume":"46","author":"JH Kang","year":"2013","unstructured":"Kang, J. H., Lee, G. W., Shin, S. H. & Bruera, E. Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis. J. Pain Symp. Manage. 46, e15 (2013).","journal-title":"J. Pain Symp. Manage."},{"key":"13085_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/2049463716657363","volume":"10","author":"RM Langford","year":"2016","unstructured":"Langford, R. M., Knaggs, R., Farquhar-Smith, P. & Dickenson, A. H. Is tapentadol different from classical opioids? A review of the evidence. Br. J. Pain 10, 217\u2013221 (2016).","journal-title":"Br. J. Pain"},{"key":"13085_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.5055\/jom.2015.0289","volume":"11","author":"DM Biondi","year":"2015","unstructured":"Biondi, D. M., Xiang, J., Etropolski, M. & Moskovitz, B. Tolerability and efficacy of tapentadol extended release in elderly patients \u226575 years of age with chronic osteoarthritis knee or low back pain. J. Opioid Manage. 11, 393\u2013403 (2015).","journal-title":"J. Opioid Manage."},{"key":"13085_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41397-019-0118-9","volume":"20","author":"B Planelles","year":"2020","unstructured":"Planelles, B. et al. Gender based differences, pharmacogenetics and adverse events in chronic pain management. Pharmacogenom. J. 20, 320\u2013328 (2020).","journal-title":"Pharmacogenom. J."},{"key":"13085_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/aas.13243","volume":"63","author":"B Planelles","year":"2019","unstructured":"Planelles, B. et al. Health benefits of an adverse events reporting system for chronic pain patients using long-term opioids. Acta Anaesthesiol. Scand. 63, 248\u2013258 (2019).","journal-title":"Acta Anaesthesiol. Scand."},{"key":"13085_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2165\/11533440-000000000-00000","volume":"30","author":"M Afilalo","year":"2010","unstructured":"Afilalo, M. et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo-and active-controlled phase III study. Clin. Drug Investig. 30, 489\u2013505 (2010).","journal-title":"Clin. Drug Investig."},{"key":"13085_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/2042098618760939","volume":"9","author":"C Abeyaratne","year":"2018","unstructured":"Abeyaratne, C., Lalic, S., Bell, J. S. & Ilom\u00e4ki, J. Spontaneously reported adverse drug events related to tapentadol and oxycodone\/naloxone in Australia. Ther. Adv. Drug Saf. 9, 197\u2013205 (2018).","journal-title":"Ther. Adv. Drug Saf."},{"key":"13085_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12871-017-0383-6","volume":"17","author":"G Haeseler","year":"2017","unstructured":"Haeseler, G. et al. Combatting pain after orthopedic\/trauma surgery-perioperative oral extended-release tapentadol vs extended-release oxycodone\/naloxone. BMC Anesthesiol. 17, 91 (2017).","journal-title":"BMC Anesthesiol."},{"key":"13085_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/papr.12361","volume":"16","author":"R Baron","year":"2016","unstructured":"Baron, R. et al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone\/naloxone PR in patients with severe chronic low back pain with a neuropathic component: A randomized, controlled, open-label, phase 3b\/4 trial. Pain Pract. 16, 600\u2013619 (2016).","journal-title":"Pain Pract."},{"key":"13085_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/hmg\/ddi013","volume":"14","author":"L Diatchenko","year":"2005","unstructured":"Diatchenko, L. et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum. Mol. Genet. 14, 135\u2013143 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"13085_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0301-0082(02)00008-4","volume":"66","author":"BL Kieffer","year":"2002","unstructured":"Kieffer, B. L. & Gav\u00e9riaux-Ruff, C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 66, 285\u2013306 (2002).","journal-title":"Prog. Neurobiol."},{"key":"13085_CR19","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1093\/hmg\/9.19.2895","volume":"9","author":"MR Hoehe","year":"2000","unstructured":"Hoehe, M. R. et al. Sequence variability and candidate gene analysis in complex disease: Association of \u03bc opioid receptor gene variation with substance dependence. Hum. Mol. Genet. 9, 2895\u20132908 (2000).","journal-title":"Hum. Mol. Genet."},{"key":"13085_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0298-7","author":"JN Ablin","year":"2013","unstructured":"Ablin, J. N. & Buskila, D. Personalized treatment of pain. Curr. Rheumatol. Rep. https:\/\/doi.org\/10.1007\/s11926-012-0298-7 (2013).","journal-title":"Curr. Rheumatol. Rep."},{"key":"13085_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0304-3959(79)90012-5","volume":"7","author":"JJ Bonica","year":"1979","unstructured":"Bonica, J. J. The relation of injury to pain. Pain 7, 203\u2013207 (1979).","journal-title":"Pain"},{"key":"13085_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/B978-0-12-381326-8.00010-7","volume":"95","author":"O Kambur","year":"2010","unstructured":"Kambur, O. & M\u00e4nnist\u00f6, P. T. Catechol-O-methyltransferase and pain. Int. Rev. Neurobiol. 95, 227\u2013279 (2010).","journal-title":"Int. Rev. Neurobiol."},{"key":"13085_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.36076\/ppj.2014\/17\/401","volume":"17","author":"CW Cheung","year":"2014","unstructured":"Cheung, C. W. et al. Chronic opioid therapy for chronic non-cancer pain: A review and comparison of treatment guidelines. Pain Phys. 17, 401\u2013414 (2014).","journal-title":"Pain Phys."},{"key":"13085_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.pain.2006.05.024","volume":"125","author":"L Diatchenko","year":"2006","unstructured":"Diatchenko, L. et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 125, 216\u2013224 (2006).","journal-title":"Pain"},{"key":"13085_CR25","first-page":"4298","volume":"2014","author":"U Melia","year":"2014","unstructured":"Melia, U. et al. Interaction between EEG and drug concentration to predict response to noxious stimulation during sedation-analgesia: Effect of the A118G genetic polymorphism. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. 2014, 4298\u20134301 (2014).","journal-title":"Annu. Int. Conf. IEEE Eng. Med. Biol. Soc."},{"key":"13085_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pbb.2013.10.018","volume":"123","author":"RC Crist","year":"2014","unstructured":"Crist, R. C. & Berrettini, W. H. Pharmacogenetics of OPRM1. Pharmacol. Biochem. Behav. 123, 25 (2014).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"13085_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/JPR.S42040","volume":"6","author":"E Mura","year":"2013","unstructured":"Mura, E. et al. Consequences of the 118A>G polymorphism in the OPRM1 gene: Translation from bench to bedside? J. Pain Res. 6, 331 (2013).","journal-title":"J. Pain Res."},{"key":"13085_CR28","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/sj.npp.1301543","volume":"33","author":"PJ Harrison","year":"2008","unstructured":"Harrison, P. J. & Tunbridge, E. M. Catechol-O-methyltransferase (COMT): A gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology 33, 3037\u20133045 (2008).","journal-title":"Neuropsychopharmacology"},{"key":"13085_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40261-013-0102-0","volume":"33","author":"I Steigerwald","year":"2013","unstructured":"Steigerwald, I. et al. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin. Drug Investig. 33, 607\u2013619 (2013).","journal-title":"Clin. Drug Investig."},{"key":"13085_CR30","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1097\/PR9.0000000000000877","volume":"5","author":"T van de Donk","year":"2020","unstructured":"van de Donk, T. et al. Tapentadol treatment results in long-term pain relief in patients with chronic low back pain and associates with reduced segmental sensitization. PAIN Rep. 5, e877 (2020).","journal-title":"PAIN Rep."},{"key":"13085_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","volume":"8","author":"J Pergolizzi","year":"2008","unstructured":"Pergolizzi, J. et al. Opioids and the management of chronic severe pain in the elderly: Consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 8, 287\u2013313 (2008).","journal-title":"Pain Pract."},{"key":"13085_CR32","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1185\/03007995.2010.502748","volume":"26","author":"A Jespersen","year":"2010","unstructured":"Jespersen, A. et al. Is neuropathic pain underdiagnosed in musculoskeletal pain conditions? The Danish PainDETECTive study. Curr. Med. Res. Opin. 26, 2041\u20132045. https:\/\/doi.org\/10.1185\/03007995.2010.502748 (2010).","journal-title":"Curr. Med. Res. Opin."},{"key":"13085_CR33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup, N. B. et al. Pharmacotherapy for neuropathic pain in adults: Systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol. 14, 162 (2015).","journal-title":"Lancet Neurol."},{"key":"13085_CR34","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1185\/03007995.2014.894501","volume":"30","author":"F Coluzzi","year":"2014","unstructured":"Coluzzi, F. & Ruggeri, M. Clinical and economic evaluation of tapentadol extended release and oxycodone\/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr. Med. Res. Opin. 30, 1139\u20131151. https:\/\/doi.org\/10.1185\/03007995.2014.894501 (2014).","journal-title":"Curr. Med. Res. Opin."},{"key":"13085_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/1158413-S0-000000000-00000","volume":"30","author":"A Gatti","year":"2010","unstructured":"Gatti, A. et al. Effects of opioid rotation in chronic pain patients. Clin. Drug Investig. 30, 39\u201347 (2010).","journal-title":"Clin. Drug Investig."},{"key":"13085_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/11630050-000000000-00000","volume":"32","author":"P Sarzi-Puttini","year":"2012","unstructured":"Sarzi-Puttini, P. et al. The appropriate treatment of chronic pain. Clin. Drug Investig. 32, 21\u201333 (2012).","journal-title":"Clin. Drug Investig."},{"key":"13085_CR37","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.clinthera.2013.03.016","volume":"35","author":"S Merchant","year":"2013","unstructured":"Merchant, S. et al. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain. Clin. Ther. 35, 659\u2013672 (2013).","journal-title":"Clin. Ther."},{"key":"13085_CR38","doi-asserted-by":"publisher","first-page":"e202012","DOI":"10.1001\/jamanetworkopen.2020.2012","volume":"3","author":"A Stokes","year":"2020","unstructured":"Stokes, A. et al. Association of obesity with prescription opioids for painful conditions in patients seeking primary care in the US. JAMA Netw. Open 3, e202012 (2020).","journal-title":"JAMA Netw. Open"},{"key":"13085_CR39","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jopan.2019.03.007","volume":"34","author":"EN Aroke","year":"2019","unstructured":"Aroke, E. N. & Hicks, T. L. Pharmacogenetics of postoperative nausea and vomiting. J. Perianesthesia Nurs. 34, 1088\u20131105 (2019).","journal-title":"J. Perianesthesia Nurs."},{"key":"13085_CR40","first-page":"97","volume":"22","author":"C Margarit","year":"2019","unstructured":"Margarit, C. et al. OPRM1 gene interaction with sleep in chronic pain patients treated with opioids. Pain Phys. 22, 97\u2013107 (2019).","journal-title":"Pain Phys."},{"key":"13085_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004235","author":"J Oh","year":"2020","unstructured":"Oh, J., Fernando, A., Muffley, L., Honari, S. & Gibran, N. S. Correlation between the warrior\/worrier gene on post burn pruritus and scarring: A prospective cohort study. Ann. Surg. https:\/\/doi.org\/10.1097\/SLA.0000000000004235 (2020).","journal-title":"Ann. Surg."},{"key":"13085_CR42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.revmed.2016.12.005","volume":"38","author":"B Ranque","year":"2017","unstructured":"Ranque, B. & Nardon, O. Prise en charge des sympt\u00f4mes m\u00e9dicalement inexpliqu\u00e9s en m\u00e9decine interne: Un paradigme de la relation m\u00e9decin-malade en situation d\u2019incertitude. Rev. Med. Interne 38, 458\u2013466 (2017).","journal-title":"Rev. Med. Interne"},{"key":"13085_CR43","doi-asserted-by":"publisher","DOI":"10.4415\/ANN_16_02_09","author":"S Pieretti","year":"2016","unstructured":"Pieretti, S. et al. Gender differences in pain and its relief. Ann. Ist. Super. Sanita. https:\/\/doi.org\/10.4415\/ANN_16_02_09 (2016).","journal-title":"Ann. Ist. Super. Sanita."},{"key":"13085_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2013.07.002","author":"RJ Traub","year":"2013","unstructured":"Traub, R. J. & Ji, Y. Sex differences and hormonal modulation of deep tissue pain. Front. Neuroendocrinol. https:\/\/doi.org\/10.1016\/j.yfrne.2013.07.002 (2013).","journal-title":"Front. Neuroendocrinol."},{"key":"13085_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-019-0118-9","author":"B Planelles","year":"2020","unstructured":"Planelles, B. et al. Gender based differences, pharmacogenetics and adverse events in chronic pain management. Pharmacogenom. J. https:\/\/doi.org\/10.1038\/s41397-019-0118-9 (2020).","journal-title":"Pharmacogenom. J."},{"key":"13085_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/6358624","volume":"2018","author":"A Samulowitz","year":"2018","unstructured":"Samulowitz, A., Gremyr, I., Eriksson, E. & Hensing, G. \u2018Brave men\u2019 and \u2018emotional women\u2019: A theory-guided literature review on gender bias in health care and gendered norms towards patients with chronic pain. Pain Res. Manage. 2018, 1\u201314 (2018).","journal-title":"Pain Res. Manage."},{"key":"13085_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5498\/wjp.v6.i1.7","volume":"6","author":"N Sharma","year":"2016","unstructured":"Sharma, N., Chakrabarti, S. & Grover, S. Gender differences in caregiving among family\u2014Caregivers of people with mental illnesses. World J. Psychiatry 6, 7 (2016).","journal-title":"World J. Psychiatry"},{"key":"13085_CR48","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S1474-4422(10)70143-5","volume":"9","author":"R Baron","year":"2010","unstructured":"Baron, R., Binder, A. & Wasner, G. Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 9, 807\u2013819 (2010).","journal-title":"Lancet Neurol."},{"key":"13085_CR49","doi-asserted-by":"publisher","first-page":"084","DOI":"10.26502\/aimr.0061","volume":"4","author":"J Barrachina","year":"2021","unstructured":"Barrachina, J. et al. Global pain state questionnaire: Reliability, validity, and gender gap. Arch. Intern. Med. Res. 4, 084\u2013106 (2021).","journal-title":"Arch. Intern. Med. Res."},{"key":"13085_CR50","unstructured":"Spanish Agency for Medicines and Health Products. Online Information Center of Medicines of Spanish Agency of Medicines and Health Products (AEMPS-CIMA). https:\/\/cima.aemps.es\/cima\/publico\/home.html (2016). Accessed 9 Sept 2020."},{"key":"13085_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2050-6511-14-39","volume":"14","author":"CG Sino","year":"2013","unstructured":"Sino, C. G. et al. The association between prescription change frequency, chronic disease score and hospital admissions: A case control study. BMC Pharmacol. Toxicol. 14, 39 (2013).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"13085_CR52","volume-title":"Benefit-Risk Methodology Project. Development and Testing of Tools and Processes for Balancing Multiple Benefits and Risks as an Aid to Informed Regulatory Decisions About Medicinal Products","author":"GC Rojas","year":"2009","unstructured":"Rojas, G. C. et al. Benefit-Risk Methodology Project. Development and Testing of Tools and Processes for Balancing Multiple Benefits and Risks as an Aid to Informed Regulatory Decisions About Medicinal Products (The European Medicines Agency, 2009)."},{"key":"13085_CR53","volume-title":"Benefit-Risk Methodology Project Work Package 2 Report: Applicability of Current Tools and Processes for Regulatory Benefit-Risk Assessment","author":"European Medicines Agency","year":"2010","unstructured":"European Medicines Agency. Benefit-Risk Methodology Project Work Package 2 Report: Applicability of Current Tools and Processes for Regulatory Benefit-Risk Assessment (European Medicines Agency, 2010)."},{"key":"13085_CR54","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1185\/03007995.2013.791617","volume":"29","author":"S Mercadante","year":"2013","unstructured":"Mercadante, S. et al. Opioid switching from and to tapentadol extended release in cancer patients: Conversion ratio with other opioids. Curr. Med. Res. Opin. 29, 661\u2013666 (2013).","journal-title":"Curr. Med. Res. Opin."},{"key":"13085_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008921.pub2","author":"BL Richards","year":"2012","unstructured":"Richards, B. L., Whittle, S. L. & Buchbinder, R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD008921.pub2 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"13085_CR56","first-page":"1","volume":"10","author":"K Mathieson","year":"2014","unstructured":"Mathieson, K. Making sense of biostatistics: Types of nonprobability sampling. J. Clin. Res. Best Pract. 10, 1\u20132 (2014).","journal-title":"J. Clin. Res. Best Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13085-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13085-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13085-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:13:39Z","timestamp":1669353219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13085-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13085"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13085-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"9 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10126"}}